The Fragility of the U.S. Vaccine Supply
- 2 December 2004
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (23) , 2443-2447
- https://doi.org/10.1056/nejmsb033394
Abstract
The authors discuss the vaccine industry in the United States and explain why the nation is vulnerable to vaccine shortages. They describe the Institute of Medicine's proposal for a federal subsidy program to provide stronger incentives for companies to develop new vaccines and to manufacture existing ones.Keywords
This publication has 12 references indexed in Scilit:
- Static and Dynamic Effects of Health Policy: Evidence from the Vaccine IndustryThe Quarterly Journal of Economics, 2004
- The Political Economy Of FDA Drug Review: Processing, Politics, And Lessons For PolicyHealth Affairs, 2004
- Strengthening the Supply of Routinely Recommended Vaccines in the United StatesJAMA, 2003
- Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and FranceJournal of Health Politics, Policy and Law, 2003
- Setting prices for new vaccines (in advance).International Journal of Health Economics and Management, 2003
- Comparative Cost Effectiveness of Varicella, Hepatitis A, and Pneumococcal Conjugate VaccinesPreventive Medicine, 2001
- The Cost to Immunize During Well-Child VisitsAmerican Journal of Medical Quality, 2001
- Is Reimbursement for Childhood Immunizations Adequate? Evidence from Two Rural Areas in ColoradoPublic Health Reports®, 2001
- Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.Archives of Pediatrics & Adolescent Medicine, 2000
- Impact of free vaccine and insurance status on physician referral of children to public vaccine clinicsPublished by American Medical Association (AMA) ,1997